Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

Vertex's growth trajectory could be significantly impacted if new product launches, particularly suzetrigine for acute pain and CASGEVY for sickle cell disease, fail to meet expectations.

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.